Healthcare provider profile · identity verified

Marina Rosa Flecha, MD

Internal Medicine · LONGMONT, CO · NPI 1700382025

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	279	84
Levothyroxine Sodium	Levothyroxine Sodium	248	73
Amlodipine Besylate	Amlodipine Besylate	208	60
Losartan Potassium	Losartan Potassium	166	46
Lisinopril	Lisinopril	163	41
Gabapentin	Gabapentin	150	49
Omeprazole	Omeprazole	146	49
Lorazepam	Lorazepam	89	18
Trazodone Hcl	Trazodone Hcl	89	27
Metformin Hcl	Metformin Hcl	86	28
Rosuvastatin Calcium	Rosuvastatin Calcium	80	27
Oxycodone Hcl	Oxycodone Hcl	79	15
Bupropion Xl	Bupropion Hcl	76	22
Metoprolol Succinate	Metoprolol Succinate	76	23
Pantoprazole Sodium	Pantoprazole Sodium	71	22
Albuterol Sulfate Hfa	Albuterol Sulfate	70	35
Fluoxetine Hcl	Fluoxetine Hcl	69	20
Duloxetine Hcl	Duloxetine Hcl	67	19
Metoprolol Tartrate	Metoprolol Tartrate	59	17
Simvastatin	Simvastatin	58	19
Tramadol Hcl	Tramadol Hcl	58	23
Hydrochlorothiazide	Hydrochlorothiazide	55	18
Ozempic	Semaglutide	55	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	52	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	51	20
Synthroid	Levothyroxine Sodium	49	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	19
Fluticasone Propionate	Fluticasone Propionate	48	20
Furosemide	Furosemide	47	20
Alendronate Sodium	Alendronate Sodium	46	15
Sertraline Hcl	Sertraline Hcl	46	15
Metformin Hcl Er	Metformin Hcl	45	12
Tamsulosin Hcl	Tamsulosin Hcl	45	17
Warfarin Sodium	Warfarin Sodium	45	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	45	15
Pregabalin	Pregabalin	40	11
Oxybutynin Chloride Er	Oxybutynin Chloride	39	suppressed
Alprazolam	Alprazolam	37	15
Carvedilol	Carvedilol	36	13
Montelukast Sodium	Montelukast Sodium	36	suppressed
Diazepam	Diazepam	35	suppressed
Lamotrigine	Lamotrigine	33	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Paroxetine Hcl	Paroxetine Hcl	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Eliquis	Apixaban	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	11
Famotidine	Famotidine	27	suppressed
Ondansetron Odt	Ondansetron	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Potassium Chloride	Potassium Chloride	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Nystatin	Nystatin	23	suppressed
Allopurinol	Allopurinol	22	suppressed
Cephalexin	Cephalexin	22	15
Azithromycin	Azithromycin	21	18
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	16
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Mounjaro	Tirzepatide	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Celecoxib	Celecoxib	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Estradiol	Estradiol	17	11
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	16
Buspirone Hcl	Buspirone Hcl	16	suppressed
Carbamazepine Er	Carbamazepine	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Prednisone	Prednisone	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Azelastine-Fluticasone	Azelastine/Fluticasone	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Varenicline Tartrate	Varenicline Tartrate	13	suppressed
Calcitriol	Calcitriol	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Nitroglycerin	Nitroglycerin	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Progesterone	Progesterone, Micronized	12	suppressed
Valsartan	Valsartan	12	suppressed
Xanax	Alprazolam	12	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	11	suppressed
Cholestyramine Light	Cholestyramine	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Trulicity	Dulaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error